Table 3.
Influenza A virus and SARS-CoV-2 replication inhibitory effect.
| Influenza A Puerto Rico 8/34/H1N1 |
SARS-CoV-2d |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cpd | MDCK |
A549 |
Huh7 |
Caco-2 |
Vero E6 |
Calu-3 |
||||||||||||
| CC50a (μM) | IC50b (μM) | SIc | CC50 (μM) | IC50 (μM) | SI | CC50 (μM) | IC50 (μM) | SI | CC50 (μM) | IC50 (μM) | SI | CC50 (μM) | IC50 (μM) | SI | CC50 (μM) | IC50 (μM) | SI | |
| 6c | 77.0 | 14.0 | 5.5 | 58.0 | 20.8 | 2.8 | NDe | ND | – | ND | ND | – | ND | ND | – | ND | ND | – |
| 6i | 77.0 | 5.3 | 14.5 | 106.0 | 9.9 | 11 | 200 | 2.7 ± 0.1 | 74 | 81.3 | 5.9 ± 1.8 | 14 | 200.0 | 53.4 ± 1.1 | 4 | 120.0 | 0.5 ± 0.1 (1.9 ± 0.4)f | 240 |
| 10a | 136.0 | 6.3 | 21.6 | 52.4 | 14.9 | 3.5 | ND | ND | – | ND | ND | – | ND | ND | – | ND | ND | – |
| RBV | (>50) | (9.5)34 | (>5.3) | (>50) | (37.4)34 | (>1.3) | ND | ND | – | ND | ND | – | (>400) | (109.5)36 | – | ND | ND | – |
| RMD | ND | ND | – | ND | ND | – | 77 | 0.004 ± 0.005 (0.002) [37] | 19250 | 80.0 | 0.01 ± 0.006 (0.38) [39] | 8000 | 166.0 | 6.0 ± 1.1 (26.9) [38] | 28 | 97.0 | 0.11 ± 0.04 (0.28) [37] | 882 |
| CMT | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 200.0 | 0.82 ± 0.32 (0.04 ± 0.01)f | 243 |
a
CC50: half-maximal cytotoxic concentration (μM).
b
IC50: half-maximal inhibitory concentration, each value is the mean of three experiments ± standard deviation (SD) at 0.01 MOI.
c
SI: selectivity index (SI = CC50/IC50).
d
IC50: half-maximal inhibitory concentration calculated through DYRA.
e
ND: Not determined.
f
IC50 calculated incubating with the ENTRY-DYRA protocol. Literature antiviral data for Remdesivir (RMD) and Ribavirin (RBV) are reported in parenthesis. CMT: Camostat. DMSO was used as control in all cytotoxicity and antiviral assays.